Protalix BioTherapeutics, Inc. (PLX) Friday said its product ELELYSO has been approved in Canada for the treatment of Gaucher Disease in both adult and pediatric patients.
Pfizer Inc. (PFE), the commercial partner of Protalix will market ELELYSO in Canada.
Einat Brill Almon, Protalix's Senior Vice President of Product Development, commented: "With the Canadian approval of ELELYSO, the drug is now approved for patients in more than ten countries across the globe" ELELYSO was approved in the U.S. in 2012.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.